The primary purpose of this study is to evaluate the efficacy of (SEROQUEL SR™ ) quetiapine fumarate sustained-release (SR) compared to placebo in the treatment of anxiety symptoms in patients with generalized anxiety disorder (GAD).

PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

Inclusion Criteria:

• Male or female aged 18 to 65 years;
• A diagnosis of generalized anxiety disorder;
• Absence of current episode of major depression.

Exclusion Criteria:

• The presence or history of schizophrenia and other psychotic disorders;
• Hypertension;
• A current diagnosis of cancer, unless in remission for at least 5 years